A Phase I study of acivicin in refractory pediatric solid tumors - A Pediatric Oncology Group study

Sylvain Baruchel, Mark Bernstein, V. Michael Whitehead, Susan Devine, Beverly Bell, Ronald Dubowy, Holcombe Grier, Cynthia Kretschmar, Anne Marie Langevin, Teresa Vietti

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study of the glutamine antagonist acivicin given intravenously over thirty minutes daily for five days. The major toxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M2 daily for five days. Six patients including three patients with brain tumor had stable disease.

Original languageEnglish (US)
Pages (from-to)211-215
Number of pages5
JournalInvestigational New Drugs
Volume13
Issue number3
DOIs
StatePublished - Sep 1995

Keywords

  • Phase I study
  • brain tumor
  • glutamine
  • glutathione

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A Phase I study of acivicin in refractory pediatric solid tumors - A Pediatric Oncology Group study'. Together they form a unique fingerprint.

Cite this